Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Polycystic Kidney Disease (PKD) Therapeutics Pipeline Report 2017 - Clinical Trials & Results, Patents, Designations and Collaborations -

Research and Markets
Posted on: 07 Mar 18

The "Polycystic Kidney Disease (PKD) Therapeutics Pipeline, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to's offering.

The study analyzed that the polycystic kidney disease (PKD) therapeutics pipeline comprises approximately 16 drug candidates in different stages of development.

According to research findings, most of the drug candidates of the PKD are being developed to be administered by the oral route.

Many pharmaceutical companies are involved in the development of therapeutic compounds by overcoming the challenges, that are effective in the treatment of PKD. They are focusing on developing the maximum drug candidates in the Pre-Clinical and Discovery stage of development. The pipeline consists of approximately eight drug candidates in the Pre-Clinical stage. GLG Pharma is in the process of developing two drug candidates in Pre-Clinical stage.

Novatarg Pharmaceuticals, received $3.2 million funding by Small Business Innovation Research (SBIR), a part of governmental agencies of National Institutes of Health, to further conduct clinical study in PKD. Novatarg Pharmaceuticals, is in the process of research and development activities of NT 1044. Through the funding, NovaTarg Pharmaceuticals had further planned to progress drug candidates for PKD and type II diabetes mellitus. In addition, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is also supporting the pharmaceutical companies to conduct clinical study and research on PKD to improve patient health.

Some of the key players developing drugs for the treatment of PKD therapeutics include Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., and XORTX Pharma Corp.

Report Segmentation

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered:

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Key Drivers

4.3 Key Barriers

4.4 Polycystic Kidney Diseases Therapeutics Pipeline Analysis

Chapter 5. Polycystic Kidney Diseases Therapeutics Pipeline Analysis by Phase (2017)

5.1 Filed: Drug profiles

5.2 Phase II: Drug profiles

5.3 Phase I: Drug profiles

5.4 Pre-Clinical: Drug profiles

5.5 Discovery: Drug profiles

5.6 Inactive: Drug profiles

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Polycystic Kidney Disease Therapeutics Pipeline

7.2 SWOT Analysis of Polycystic Kidney Disease Therapeutics Pipeline

Chapter 8. Company Profiles

  • Exelixis, Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • XORTX Pharma Corp

For more information about this report visit

View source version on

Business Wire

Last updated on: 07/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.